Daiichi Sankyo

Latest Headlines

Latest Headlines

Daiichi Sankyo, Sanofi to launch DPT-polio vaccine in Japan

In the latest of a string a partnerships forged this year, Daiichi Sankyo is teaming up with Sanofi's Japanese unit to launch Squarekids subcutaneous injection syringe, a tetravalent vaccine for the prevention of diphtheria, pertussis, tetanus and polio.

Daiichi loses Supreme Court decision on Apotex generic

The U.S. Supreme Court dealt a blow to Daiichi Sankyo and Mylan Pharmaceuticals when the court declined to hear their appeal in their attempt to head off drugmaker Apotex from introducing a generic version of the hypertension drug Benicar.

Daiichi Sankyo and Plexxikon get FDA nod for melanoma combination

Japan's Daiichi Sankyo and its associated company Plexxikon said the U.S. Food and Drug Administration (FDA) has approved cobimetinib for the treatment of people with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf (vemurafenib), the company said in a statement.

Struggling Daiichi stumbles with vaccine production again

As if Daiichi Sankyo didn't have trouble enough, the struggling Japanese drugmaker, which is laying off thousands of employees to cut costs, is again having issues with its vaccine production.

Daiichi Sankyo's cancer drug wins the FDA's coveted 'breakthrough' tag

Daiichi Sankyo picked up the FDA's breakthrough therapy designation for a Phase III cancer drug, putting it in line for preferential access to agency experts as it moves toward approval.

Japan's Daiichi Sankyo to cut as many as 1,200 U.S. jobs in reorganization

Japan's Daiichi Sankyo will cut as many as 1,200 jobs in the U.S. as it braces for the loss of patent protection on top treatment Benicar and shakes up the organization for a transition to a specialty portfolio in cardiovascular, pain management and oncology.

Struggling Daiichi plots another 1,000-plus job cuts in U.S.

Japan-based drugmaker Daiichi Sankyo will cut up to 1,200 jobs in the U.S., about half its workforce in its stateside subsidiary, Nikkei reports. The announcement follows a series of layoffs earlier this year at its Parsippany, NJ, operations.

Japan's Daiichi Sankyo goes to Memphis to license clot-busting antibody

Japan's Daiichi Sankyo has licensed a candidate to treat ischemic stroke, TS23, from Memphis-based Translational Sciences without disclosing any details on fees, milestones and royalties for exclusive global development and commercial rights

Daiichi Sankyo inks deal to market AstraZeneca's FluMist in Japan

Just in time for flu season, AstraZeneca granted Daiichi Sankyo an exclusive license to market its FluMist Quadrivalent in Japan. The live attenuated vaccine, delivered nasally, went through Phase III trials in Japanese children, and a regulatory submission is being prepared for Japan.

Daiichi clot-buster wins a NICE green light, but still faces an uphill track

As the fourth market entrant in a hotly contested group of new-age anticoagulants, Daiichi Sankyo's Lixiana (edoxaban) has some ground to make up. Luckily, it got a boost in the U.K. that could help it build momentum.